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Human adipose-derived stem cell transplantation
as a potential therapy for collagen VI-related
congenital muscular dystrophy
Vitali Alexeev1, Machiko Arita1, Adele Donahue1, Paolo Bonaldo2, Mon-Li Chu1 and Olga Igoucheva1*

Abstract
Introduction: Congenital muscular dystrophies (CMD) are a clinically and genetically heterogeneous group of
neuromuscular disorders characterized by muscle weakness within the first two years of life. Collagen VI-related
muscle disorders have recently emerged as one of the most common types of CMD. COL6 CMD is caused by
deficiency and/or dysfunction of extracellular matrix (ECM) protein collagen VI. Currently, there is no specific
treatment for this disabling and life-threatening disease. The primary cellular targets for collagen VI CMD therapy
are fibroblasts in muscle, tendon and skin, as opposed to muscle cells for other types of muscular dystrophies.
However, recent advances in stem cell research have raised the possibility that use of adult stem cells may provide
dramatic new therapies for treatment of COL6 CMD.
Methods: Here, we developed a procedure for isolation of human stem cells from the adipose layer of neonatal
skin. The adipose-derived stem cells (ADSC) were examined for expression of ECM and related genes using gene
expression array analysis. The therapeutic potential of ADSC was assessed after a single intramuscular transplantation
in collagen VI-deficient mice.
Results: Analysis of primary cultures confirmed that established ADSC represent a morphologically homogenous
population with phenotypic and functional features of adult mesenchymal stem cells. A comprehensive gene
expression analysis showed that ADSC express a vast array of ECM genes. Importantly, it was observed that ADSC
synthesize and secrete all three collagen VI chains, suggesting suitability of ADSC for COL6 CMD treatment.
Furthermore, we have found that a single intramuscular transplantation of ADSC into Col6a1−/−Rag1−/− mice under
physiological and cardiotoxin-induced injury/regeneration conditions results in efficient engraftment and migration
of stem cells within the skeletal muscle. Importantly, we showed that ADSC can survive long-term and continuously
secrete the therapeutic collagen VI protein missing in the mutant mice.
Conclusions: Overall, our findings suggest that stem cell therapy can potentially provide a new avenue for the
treatment of COL6 CMD and other muscular disorders and injuries.

Introduction
Knowledge of the genetic and molecular mechanisms
underlying congenital muscular dystrophies (CMDs) has
dramatically advanced in the past decade [1]. However,
treatment options for CMDs have remained limited and
there is no cure for this group of disabling and often lethal
disorders. The CMDs present with muscle pathologies
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similar to those seen in traditional muscular dystrophies,
of which Duchenne and Becker muscular dystrophies
are the major forms. However, the mechanisms leading
to the muscle pathologies (sarcolemma instability, degeneration and regeneration of muscle cells, apoptosis and
fibrosis) differ between the common CMD types and other
muscular dystrophies. Gene mutations that result in disturbed interactions between extracellular matrix (ECM)
and muscle cells underlie the most prevalent CMD types,
that is COL6 CMD, LAMA2 CMD or MCD1A, and various forms of α-dystroglycanopathies [2].
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COL6 CMD is the most or the second most common
CMD type in the North American, Japanese and Northern
England populations [3-5]. Disease is characterized by
muscle weakness during the first two years of life [1].
Ullrich congenital muscular dystrophy (UCMD) and
Bethlem myopathy, respectively, represent the severe and
mild end of a clinical continuum associated with a deficiency or dysfunction of collagen type VI [1,6]. Patients
afflicted with COL6 CMD manifest not only muscle weakness but also connective tissue abnormalities, including
joint contractures and distal hypermobility. Severely affected UCMD patients are never able to walk independently and suffer from respiratory failure, resulting in early
death. The disease is caused by dominant or recessive mutations in the genes encoding collagen VI subunits [1].
Collagen VI is produced by diverse connective tissue cell
types in almost all organs. In the skeletal muscle, collagen
VI is synthesized by muscle fibroblasts but not by muscle
cells [7,8]. The protein is composed of different subunits
and the most common form is made up of α1(VI), α2(VI)
and α3(VI) collagen chains, encoded by the COL6A1,
COL6A2 and COL6A3 genes, respectively [9]. The severe
UCMD phenotype is caused by either recessive or dominant negative mutations in any of the three collagen VI
genes [1]. The recessive UCMD patients typically have
nonsense or frameshift mutations, resulting in a complete
absence or drastic reduction of the collagen VI protein
[10-12]. In COL6 CMD, the proteins at fault reside outside
of the muscle cells, which is in stark contrast to most
other muscular dystrophies, in which the gene mutations
usually involve cellular proteins produced by muscle cells.
Thus, even though several therapeutic approaches have
been explored for traditional muscular dystrophies, there
is a need to develop treatment strategies that specifically
target muscle ECM alterations.
A mouse mutant lacking the α1(VI) collagen chain, the
Col6a1−/− mouse generated by gene targeting, has served
as a model for recessive UCMD [13]. Like the mouse
model for Duchenne muscular dystrophy, the phenotype
of the Col6a1−/− mice is significantly milder than that of
the recessive UCMD patients with a total absence of collagen VI protein. The Col6a1−/− mice have normal life spans
and their skeletal muscles display relatively mild myopathic pathology, including variation in muscle fiber diameter and the presence of muscle fibers with centrally
localized nuclei. Physiological assessment of the muscles
has demonstrated a loss of contractile strength, in that
tetanic and twitch tensions were significantly reduced.
Myoblasts from the Col6a1−/− mice and UCMD patients
have been shown to display a latent mitochondrial dysfunction that predisposes muscle fibers to apoptosis
[14,15]. The abnormality in mitochondria and increase
in apoptosis have recently been demonstrated to result
from defective autophagy [16]. This has led to a pilot
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treatment (one month) and a long-term trial (1 to
3.2 years) of a small number of COL6 CMD patients in
Italy, using oral administration of cyclosporine A to inhibit
the mitochondrial dysfunction [17,18]. The long-term
cyclosporine A treatment was shown to be well tolerated
and was able to ameliorate performance in limb muscles,
but not in respiratory muscles. The results suggest that
the pharmacological treatment, although promising, is not
sufficient for treating the disease.
Stem cell-based therapy holds promise for treating
genetic diseases and has been utilized in animal models
and human clinical trials for different types of muscular
dystrophies, in particular Duchenne muscular dystrophy
[19]. The majority of these studies evaluated the ability
of muscle-derived progenitor or stem cells as well as
adult stem cells from non-muscle tissues to replace
damaged muscle fibers. However, effective cellular therapy for ECM-related CMDs rests on the ability of the
therapeutic cells to secrete normal ECM proteins that
can prevent muscle cell degeneration rather than on the
potential of these cells to differentiate into muscle fibers.
Multipotent mesenchymal stem cells (MSC) were originally isolated from bone marrow and subsequently from
many other adult tissues. MSC display extensive proliferation capacity in culture and can differentiate in vitro
into various connective tissue cell types [20,21]. These
unique features make MSC an attractive therapeutic option for COL6 CMD. Although bone marrow is the main
source for MSC isolation, subcutaneous fat represents
an alternative repository for stem cells and is currently a
subject of intensive investigations [22]. Similarly to bone
marrow-derived MSC, adipose-derived stem cells (ADSC)
can be induced to differentiate into multiple lineages
in vitro under adipogenic, osteogenic, chondrogenic, myogenic and neurogenic supplementation conditions [23].
Furthermore, ADSC can be obtained by less invasive
methods, have relatively lower donor-site morbidity and
are available in large quantities for procurement [24]. Also,
ADSC have immunoprivileged behavior in immunocompetent mouse models, suggesting their potential as immunopriviledged universal cells with the capacity to be used
in the allogeneic setting and to reduce graft-versus-host
disease [24].
In this study, we developed a procedure for the isolation
of ADSC from human neonatal foreskin and demonstrated that the established primary cultures represent a
cell population with phenotypic and functional features
of mesenchymal progenitors. We also showed that ADSC
cultured in vitro secrete a variety of ECM proteins, including collagen VI and, therefore, can provide therapeutic
ECM proteins without cell differentiation in the muscle
environment. In addition, we explored for the first time
the potential of xenogeneic ADSC in treating COL6 CMD
using Col6a1−/− mice, the animal model for recessive
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UCMD. Our results show that ADSC delivered intramuscularly are engrafted in the interstitial connective tissues
of the skeletal muscle where they continued to secrete
collagen VI and assemble collagen VI microfibrils. The
number of collagen VI positive myofibers increased
steadily over time after transplantation. The extent of
ADSC engraftment and collagen VI production was significantly higher when muscle was injured by cardiotoxin.
Our study provides the proof-of-concept evidence that
ADSC therapy has the potential to treat COL6 CMD.

were added. The cells were incubated on ice for 15 minutes. The cells were washed with depletion buffer and
centrifuged. The cell pellet was resuspended in depletion
buffer and applied to the MiniMACS magnetic field column system (Miltenyi Biotec) using the MACS MS separation column (Miltenyi Biotec). The eluted cells were
collected after several washes and centrifugation. The collected cells were designated as first passage cells and were
cultured in (D)MEM/F12 and GlutaMax™ plus 10% FBS at
37°C in a humidified 5% CO2-95% air atmosphere.

Methods

Fluorescence-activated cell sorting analysis

Mouse strains

ADSC were grown until confluent, trypsinized and pelleted
by centrifugation at 200 g for five minutes. For fluorescenceactivated cell sorting (FACS) analysis, approximately 2.5 ×
105 cells were resuspended in 100 μl FACS buffer containing
10% FBS in PBS. For FACS analysis of surface markers, each
sample was incubated for 30 minutes at 4°C with fluorescein
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated
antibodies against the following surface markers: CD45,
CD34, CD11b, CD31, CD19, CD90, CD44, CD71, CD29,
CD73, STRO-1, HLA-ABC, HLA-DR, CD117, CD105,
CD106 (eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. After incubation, the labeled
cells were diluted with 2 ml of FACS buffer, pelleted and resuspended in 500 μl of FACS buffer. Generally, approximately 104 cells were analyzed per sample using the BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA,
USA). Results were analyzed using FlowJo software.

The Col6a1−/− mice have been described previously [13].
Immunocompromised Col6a1−/− mice were generated by
crossing the Col6a1−/− and Rag1−/− (B6.129S7-Rag1tm1Mom/J,
Jackson Laboratory, Bar Harbor, ME, USA) mice. The
Col6a1−/−Rag1−/− genotype was selected by PCR. Col6a1
−/−
Rag1−/− mice were used in all ADSC transplantation
studies to avoid possible rejection of human cells.
Isolation of adipose-derived stem cells from human
neonatal foreskin and tissue culture conditions

Human adipose-derived stem cells were isolated from discarded neonatal foreskin. The study was not classified as
human subject research as per guidelines of the Thomas
Jefferson University IRB and as such did not require ethics
approval. The use of discarded tissue for research purpose
does not require patient informed consent, the hospital’s
general informed consent for surgery/procedures specifies
that the removed tissue may be collected anonymously and
used for research. Briefly, tissue samples were washed
two times in PBS plus 1% Penicillin/Streptomycin
(Gibco, Grand Island, NY, USA) and then the adipose
tissue was separated from the connective tissue using a
surgical blade. The tissue was minced and digested in
collagenase solution (0.001 g collagenase I (Sigma, St.
Louis, MO, USA) in 1 ml PBS and BSA). To obtain a single cell suspension, the digested tissue was applied to a
30 μm mesh separation filter (Miltenyi Biotec, Auburn,
CA, USA). A PBS plus 1% BSA solution was added to the
mesh to quench the enzyme and flush any remaining cells
through the filter. The suspension was centrifuged and the
pellet was resuspended in 1 ml of (D)MEM/F12 and GlutaMax™ plus 10% fetal bovine serum (FBS) (Gibco). Cells
were plated in (D)MEM/F12 and GlutaMax™ plus 10%
FBS (Invitrogen, Grand Island, NY, USA) and grown to
confluence. To remove hematopoietic cells, cells were
then depleted using magnetic separation beads. For immunodepletion, the cell pellet was resuspended in 40 μl PBS
plus 0.5% BSA plus 2 mM ethylenediaminetetraacetic acid
(EDTA) (depletion buffer), then 20 μl of CD45 microbeads
(Miltenyi Biotec), 20 μl of FcR blocking reagent (Miltenyi
Biotec) and 20 μl of CD31 microbeads (Miltenyi Biotec)

Differentiation assays

Before addition of inductive media, ADSC cultures were
grown to confluence after which the standard adipose
stem cell medium was replaced with the inductive media.
Osteogenic differentiation was induced by culturing cells
with osteoinductive medium (Lifeline Cell Technology,
Frederick, MD, USA). The cells were treated with osteogenic supplements for up to five weeks with three medium
changes per week. Cells were morphologically examined
and assessed for alkaline phosphatase (ALP) activity and
ECM calcification. Analysis of ALP activity was done using
the ALP Semiquantitative Histochemical Diagnostic Kit
(Sigma). For matrix mineralization, three-week osteogenic
cultures were fixed with 100% ethanol and analyzed using
2% Alizarin Red Stain (Lifeline Cell Technology). Cultures
were also analyzed for mRNA transcripts of ALP and
BGLAP/OCN, which denote markers of a mature osteoblast. Total RNA was isolated as described below and subjected to RT–PCR amplification using gene-specific
primers listed in Additional file 1: Table S1.
To induce adipocytic differentiation, cells were cultured in adipogenic induction medium (Lifeline Cell
Technology) for five weeks with three medium changes
per week. For histochemical examination, adipogenic
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cultures were stained for the presence of intracellular
lipid droplets using Oil Red-O staining as an indicator
of intracellular lipid accumulation. Briefly, cells were
fixed for 30 minutes in 4% paraformaldehyde (Lifeline
Cell Technology), washed with 100% 1,2-propanediol
dehydration solution (Lifeline Cell Technology) and
then stained for 30 minutes at 37°C with 0.5% Oil Red-O
solution (Lifeline Cell Technology). Adipogenic cultures were also analyzed for mRNA transcripts of LPL,
expressed in preadipocytic as well as adipocytic cells
and PPARγ2, a transcription factor expressed in mature adipocytes. The gene-specific primers are listed in
Additional file 1: Table S1.
Chondrogenic differentiation was performed using the
micromass culture technique. Briefly, 10 ml of a concentrated cell suspension, at least 1 × 106 cells, were plated
into the center of each well of a 96-well plate and
allowed to attach at 37°C for two hours. Chondrogenic
medium (Cambrex, East Rutherford, NJ, USA) was gently
overlaid so as not to detach the cells nodules. Cultures
were maintained in chondrogenic medium for up to five
weeks with three medium changes per week. Sulfated proteoglycans were specifically detected using Alcian blue
staining under acidic conditions. Briefly, cell nodules
were fixed with 10% formalin for 20 minutes and
washed extensively with PBS. Fixed cells were then incubated for 30 minutes with 1% (w/v) Alcian blue (Sigma) in
0.1 M HCl at pH 1.0 and washed with 0.1 M HCl for five
minutes to remove excess stain. Chondrogenic cultures
were also analyzed for mRNA transcripts of SOX9, COLII,
COLX, COLXI and ACAN/AGN. Gene-specific primers
are listed in Additional file 1: Table S1.
Gene expression analysis of stem cells

Total RNA from ADSC was isolated using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA, USA). A whole
human genome oligo microarray (one-color) (Agilent
Technologies, Santa Clara, CA, USA) was performed
by a service provided by Miltenyi Biotec. Briefly, the
RNA was amplified and labeled with Cy3 using the
Agilent Low Input Quick Amp Labeling Kit (Agilent
Technologies) according to the manufacturer’s protocol. The hybridization was performed according to the
Agilent 60-mer oligo microarray processing protocol
using the Agilent Gene Expression Hybridization Kit
(Agilent Technologies). All steps including amplification,
labeling and hybridization were performed as a service
by Miltenyi Biotec. Fluorescence signals of the hybridized Agilent Microarrays were detected using Agilent’s
Microarray Scanner System (Agilent Technologies). The
differential gene expression data were analyzed using the
Rosetta Resolver® gene expression data analysis system
(Rosetta Biosoftware). The complete microarray data
are available at the National Center for Biotechnology
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Information (NCBI) Gene Expression Omnibus (GEO)
repository under Series Accession Number GSE51030.

RNA isolation and RT–PCR analysis

Total RNA was isolated using the Qiagen RNeasy Mini
Kit (Qiagen). RT–PCR was conducted using the Verso
1-Step RT-PCR ReddyMix Kit (Thermo Scientific,
Waltham, MA, USA). For a standard reaction, 50 ng
of total RNA was mixed together with 200 nM each
of primers in a final volume of 25 μl. All primers and
melting temperatures (Tm) used in the study are listed in
Additional file 1: Table S1. The amplification cycles for
PCR were 50°C for 15 minutes, 95°C for 2 minutes, followed by 35 cycles of 95°C for 20 seconds, 50 to 60°C for
30 seconds and 72°C for 1 minute, followed by an additional extension for 5 minutes at 72°C. The amplified
fragments were separated on 1.5% agarose gel in 1 × Trisacetate EDTA (TAE) buffer at 100 V for one hour and
visualized with ethidium bromide staining on a GelDoc
1000 (BioRad, Hercules, CA, USA).

Western blot analysis

Denatured proteins were isolated from ADSC. Proteins were
separated by a 4% to 12% gradient SDS-polyacrylamide
gel electrophoresis (PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane followed by the
Western blot analysis using polyclonal anti-COL6A1
[25], anti-COL6A2 [26] and anti-COL6A3 antibodies
[27]. Immunocomplexes were detected by using horseradish peroxidase (HRP)-labeled anti-rabbit secondary
antibodies (Promega, Madison, WI, USA) and visualized
by using SuperSignal WestFemto substrates (Pierce,
Rockford, IL, USA).

Indirect immunofluorescent analysis

For indirect immunofluorescent analysis, cells cultured
in chamber slides (Nalgen/Nunc, Rochester, NY, USA)
were fixed with methanol at -20°C and blocked with
1% BSA in PBS for one hour at room temperature. Proteins were detected with primary antibodies generated
against collagen VI α1, α2 and α3 chains (1:1000 dilutions), respectively, for one hour at room temperature.
Immunocomplexes were detected with AlexaFluor488or AlexaFluor594-conjugated secondary antibodies (Invitrogen) at a dilution of 1:200 for one hour incubation at
room temperature. To visualize nuclei, slides were counterstained with 4′,6-diamidino-2-phenyl indol (DAPI;
1:1000 dilution) for two minutes at room temperature.
Slides were then covered with Fluorosafe reagent and
immunofluorescent images were obtained on a Nikon
TS100F fluorescent microscope.
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Transplantation of ADSC into Col6a1−/−Rag1−/− mice
under physiological and CTX-induced injury/regeneration
conditions

All animal procedures were performed in accordance with
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health publication no. 86–23) and
approved by the Institutional Animal Care and Use Committee of the Thomas Jefferson University. For all transplantation studies, ADSC (passage 2 to 4) were labeled
with a red lipophilic tracer, DiOC18 (Molecular Probes,
Grand Island, NY, USA). For therapeutic assessment of
ADSC in physiological conditions, neonatal three- to
five-day-old Col6a1−/−Rag1−/− mice (n = 5/treatment/time
point) were intramuscularly transplanted with 0.5 × 106
DiOC18-ADSC in 50 μl PBS in the gastrocnemius muscle
(GCM) of the left hindlimb. The right hindlimb was
injected with PBS and served as a control. To induce
muscle injury, Col6a1−/−Rag1−/− mice (n = 5/treatment/
time point) were injected with 10 μM cardiotoxin (CTX,
Sigma) dissolved in PBS in the GCM of the left hindlimb
two days after transplantation. The right GCMs were
injected with PBS and used as a control. For analysis,
transplanted mice were euthanized by CO2 inhalation at
predetermined time points (one, two, three, four and six
weeks) and muscle samples were collected. In vivo imaging
(IVIS) (Lumina XR, Caliper LifeSciences, Hopkinton, MA,
USA) was performed at indicated time points to determine the localization of the transplants. Transplantation
was evaluated by histopathologic, indirect immunofluorescence and molecular analyses. For all histopathologic analyses, collected tissue samples were embedded
into optimal cutting temperature (OCT) compound (VWR,
Pittsburgh, PA, USA), frozen and cryosections taken at a
thickness of 10 μm. For histological analysis, sections were
stained with H & E using a standard protocol. All samples
were evaluated for the presence of engrafted DiOC18ADSC expressing cells using fluorescence microscopy. For
indirect immunofluorescent analysis of collagen VI, crosssections were stained with anti-α1(VI) collagen rabbit
polyclonal antibodies. Immunocomplexes were detected
with AlexaFluor488- or AlexaFluor594-labeled secondary
antibodies (Invitrogen). For the analysis of co-localization
of type VI collagen and lamin A/C-positive ADSC, muscle
sections were stained with human specific monoclonal
antibodies to lamin A/C (Millipore/Chemicon, Billerica,
MA, USA) and AlexaFluor488-labeled anti-mouse immunoglobulin secondary antibodies (Invitrogen). For
the analysis of co-localization of type VI and IV collagens, sections were stained with antibodies specific to
type IV collagen (Millipore/Chemicon) and AlexaFluor594- or AlexaFluor350 labeled secondary antibodies
(Invitrogen). To examine immune response, macrophages were detected with FITC-conjugated anti-mouse
CD11b (BD Bioscience). Pax7-positive satellite cells
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were detected using anti-Pax7 (Developmental Studies
Hybridome Bank, Iowa City, IA, USA). Images were
taken and analyzed using AutoQuant imaging software
(AutoQuant Imaging Inc, Troy, NY, USA). The relative
number of the engrafted lamin A/C-positive ADSC on
cryosections was determined by semi-quantitative immunofluorescence analysis using AutoQuant imaging software. The average number of collagen α1(VI) -positive
fibers was calculated and compared between samples collected at different time points. Multiple adjacent sections
were analyzed within 20 random, non-overlapping microscopic fields per sample. All morphometric comparisons
are presented as percentages of untreated limb (baseline
control) and analyzed for statistical significance using
the Student’s t test, with P value less than 0.01 considered significant in all tests.

Results
Isolation and characterization of human adipose-derived
stem cells

We developed a novel method for the isolation of ADSC
from the neonatal skin discarded after newborn circumcision
using negative immunodepletion with a cocktail of biotinlabeled lineage-specific antibodies and magnetic cell sorting.
The original cultures of ADSC were produced as described
in the Methods section. Routinely, approximately 1 × 106
ADSC were produced from each skin sample after tissue digestion followed by negative selective depletion of mature
hematopoietic cells, such as T cells, B cells, monocytes/macrophages, granulocytes, erythrocytes and their committed
precursors. The ADSC appeared initially as adherent,
spindle-shaped cells after three to four days of culture. Then,
the cells grew rapidly, and could be easily expanded.
To determine the antigen expression profile of the
established ADSC, immuno-phenotypic analysis (FACS)
using fluorescently labeled antibodies against a panel of
cell surface markers was performed (Figure 1A). The analysis showed that the cells do not express endothelial
markers (CD31-PECAM1), hematopoietic markers (CD34,
CD45 and CD117-c-kit) or the marker for macrophages
(CD11b). However, the cells expressed high levels of CD44,
CD105 (SH2), adhesion markers (CD29-integrin β1 and
CD90-Thy-1) and mesenchymal stem cell marker CD73,
consistent with the published profile from adult adipose
tissues. Also, the ADSC were negative for HLA-class II
(HLA-DR), but positive for HLA-class I (HLA-ABC).
To verify the ability of the generated ADSC cultures to
differentiate into multiple cell types, the cells were analyzed for osteogenic, adipogenic and chondrogenic potentials in vitro. To induce osteogenic differentiation, the
cells were maintained in differentiation basal osteogenic
medium for up to five weeks. Cell cultures were morphologically examined and ALP activity and ECM calcification were assessed. As expected, the cells underwent

Alexeev et al. Stem Cell Research & Therapy 2014, 5:21
http://stemcellres.com/content/5/1/21

Page 6 of 17

Figure 1 Phenotypic analysis of primary human neonatal ADSC. (A) Immunophenotypic analysis was performed using fluorescein-conjugated
antibodies. For each sample, 10,000 events were read and the percent of positive cells expressing the respective surface marker is listed in the
box. (B) Multilineage differentiation capacity of neonatal ADSC. Cells treated with osteogenic supplements showed an increased number of
alkaline phosphatase-positive cells. Treatment of cells with adipogenic supplements resulted in the formation of adipocytic cells containing
intracellular lipid droplets as detected by oil red staining. ADSC cultured in micromass showed a chondrogenic phenotype as detected by
Alcian blue staining. (C) RT-PCR analysis of lineage-specific genes. Alkaline phosphatase (ALP) and osteocalcin (OCN) were used to indicate
commitment to the osteogenic lineage. Lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor gamma transcript variant 2
(PPARγ2) were used to indicate cells of an adipogenic lineage. SRY (sex determining region Y)-box 9 (SOX9), collagen type II (COLII), collagen
type X (COLX), collagen type XI (COLXI), and aggrecan (AGN) were used to show commitment to the chondrogenic lineage. Top row shows
the basal expression of these genes in control ADSC at 0 weeks. Bottom row shows expression of genes after three weeks of culturing in
inductive media. (D) RT-PCR analysis for the expression of COL6A1, COL6A2 and COL6A3 genes in cultured ADSC using gene-specific primers.
(E) Western blot analysis of individual (α1, α2, α3) collagen VI chains in ADSC using chain-specific antibodies. (F) Immunofluorescence analysis
of individual (α1, α2, α3) chains of collagen VI was performed using chain-specific antibodies (red) and co-stained with human lamin A/C
(green). ADSC, adipose-derived stem cells.

a dramatic change in cellular morphology from spindleshaped to cuboidal. In addition, histochemical analysis
of the cells for ALP activity showed a high and uniform
staining (Figure 1B). When the cultures were examined
for their ability to elaborate a mineralized ECM, a substantial calcium deposition was detected, while no calcium deposition was seen in control ADSC cultures (data not
shown). To verify these data, mRNA expression of the
osteogenic markers, such as ALP and osteocalcin (OCN),
was also investigated. As expected, cells under differentiation conditions showed substantial up-regulation of the
indicated osteogenic marker genes (Figure 1C), although a
low-level ALP expression could be detected in control
non-differentiated cultures.
To induce adipocytic differentiation, cells were maintained in adipogenic induction medium for five weeks.
For histochemical examination, the adipogenic culture
was stained for the presence of intracellular lipid droplets as an indicator of intracellular lipid accumulation.
Oil Red-O staining of five-week cultures for intracellular lipid vacuoles did not show any cells resembling adipocytes in control cultures, whereas upon treatment

with adipogenic inductive medium, cells with a typical
adipocyte phenotype containing intracellular lipid droplets appeared (Figure 1B). Moreover, RT-PCR analysis
showed that adipocyte-related transcripts, such as lipoprotein lipase (LPL) and peroxisome proliferator-activated
receptor γ2 (PPARγ2), were induced in differentiated
ADSC (Figure 1C).
Chondrogenic differentiation was performed using the
micromass culture technique in which cellular condensation (a critical first event of chondrogenesis) is duplicated.
Chondrogenic medium was gently overlaid so as not to
detach the cell nodules and the cultures were maintained
for up to five weeks. Under these conditions, the cells
formed nodules associated with a well-organized ECM
rich in sulfated proteoglycans as detected using Alcianblue staining under acidic conditions (Figure 1B). Nodules
were associated with an Alcian-blue-positive ECM, indicative of the presence of sulfated proteoglycans within
the matrix, whereas no obvious staining was observed in
undifferentiated control ADSC cultures. Next, cell aggregates were analyzed by RT-PCR using specific primers
for chondrogenic-related genes. As expected, aggregated
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cultures showed a marked induction of mRNAs from chondrogenic genes, including SOX9 (Figure 1C). In addition,
expression levels of COL2A1 and COL11A1 genes were also
significantly increased. Overall, our data indicate that the
neonatal ADSC generated here represent a morphologically
homogenous population with phenotypic and functional
features of adult mesenchymal stem cells and possess
the capacity to differentiate toward specific lineages when
exposed to the appropriate inductive media.
Differential expression of ECM and related genes in ADSC

To examine the expression profile of the established
ADSC, we performed a whole human genome oligo
microarray analysis with a special emphasis on ECM, adhesion molecules and related genes. The median standard deviation of identified genes across three replicates
was about 0.04, indicating good intra-array reproducibility.
Transcriptional activity was identified in all categories of
genes expressed by ADSC, including collagens, ECM and
basement membrane constituents, adhesion molecules
involved in cell-cell and cell-matrix interactions, and
proteases involved in degradation of the ECM and their
inhibitors (Table 1 and Additional file 2: Table S2). High
expression of several collagen genes was detected, including those coding for the α1 and α2 chains of collagen I, the α2 chain of collagen IV, the α1 and α2 chains
of collagen V, the α1 and α2 chains of collagen VI, the
α1 chain of collagen XII, and the α1 chain of collagen
XVI. Transcripts for many other collagens were also detectable. Moreover, relatively high expression of several
basement membrane constituents was identified, such
as the LAMB1, LAMB2 and LAMC1. In addition, other
genes with significant roles in ECM integrity were identified, such as the decorin (DCN, affects the fate of collagen
fibril formation), lumican (LUM, regulates collagen fibril
assembly) and elastin (ELN, the major component of elastic fibers, provides strength and flexibility to connective
tissue). Among cell-matrix adhesion molecules detected
were different integrins (ITGA5, ITGA7, ITGAV, ITGB1
and ITGB5) and the immunoglobulin superfamily genes
(ICAM1, ICAM2 and ICAM3). The obtained transcriptional signatures also showed that ADSC express different
transmembrane molecules, with the highest expression of
the cadherin 2 (CDH2) and to a lesser extent CDH11,
CDH13 and CHD22. Several genes participating in
ECM remodeling, including matrix metallopeptidases
(MMP1 and MMP3) and metallopeptidase inhibitors
(TIMP1, TIMP2 and TIMP3), were highly expressed in
ADSC. Interestingly, the expression analysis of genes
coding for myogenic markers showed that ADSC were
negative for the majority of them, including myogenin,
Myf5, MRF4, MyoD, Pax7 and M-cadherin. However,
the analysis revealed that ADSC express a relatively
high level of desmin (DES, helps maintain the structure
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of sarcomeres, which are necessary for muscle contraction) and low expression of the myocyte-specific enhancer
factor 2C (MEF2C, plays a role in myogenesis and, possibly, in maintaining the differentiated state of muscle
cells) and dystrophin (DMD, acts as an anchor for muscle
fibers and protects them from injury). Taken together, our
analysis shows that neonatal ADSC express a plethora of
different ECM, adhesion molecules and other ECMrelated genes.
Our gene expression analysis demonstrated that out of
all collagen types detected in ADSC, collagen type VI
(COL6A1, in particular) is the second most expressed
gene after type I collagen (COL1A1 and COL1A2). To further verify these data, expression of all three individual
chains of collagen VI in established ADSC was confirmed
by RT-PCR, western blot and immunofluorescence. The
presence of COL6A1, COL6A2 and COL6A3 transcripts
and proteins was detected using chain-specific primers
and antibodies (Figure 1D and E), respectively. These results were further confirmed by indirect immunofluorescence analysis (Figure 1F). Overall, our data demonstrate
that neonatal ADSC produce a significant level of collagen
type VI and are readily available for therapeutic protein
replacement in COL6 CMD.
Intramuscular transplantation of ADSC into
Col6a1−/−Rag1−/− mice under physiological conditions

In order to assess the potential of neonatal ADSC in
therapeutic application of COL6 CMD, fluorescently
labeled ADSC (DiOC18-ADSC) were intramuscularly
transplanted into the GCM of the left hindlimb of threeto five-day-old Col6a1−/−Rag1−/− mice. The right limb
was injected with PBS and served as internal control.
Live imaging of both transplanted and control mouse
limbs was performed every week for six weeks using the
IVIS imaging system. To measure myofibers associated
with immunoreactive α1(VI) collagen and estimate the
engraftment level of donor cells in recipient muscle tissue,
the cryosections with positive DiOC18-ADSC were coimmunostained with antibodies against α1(VI) collagen
and lamin A/C as a marker for donor human cells. As
shown in Figure 2A, the red fluorescent signals of
DiOC18-labeled ADSC were detectable in all transplanted
limbs throughout the study but not in the control hindlimbs. Based on morphometric analysis, the GCM receiving an ADSC transplant showed extensive engraftment as
judged by the presence of lamin A/C-positive cells on
muscle cryosections (Figure 2B). Moreover, we found that
the level of engraftment did not change significantly and
sustained at the level of 20% up to six weeks after transplantation. Analysis of the transplanted GCM of recipient
limbs revealed a robust, time-dependent engraftment and
distribution of collagen VI-positive myofibers (Figure 3). It
is interesting to note that during the first week after
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Table 1 Differential expression analysis in primary human neonatal ADSC
Signal Fold difference gene/GAPDHa

Gene symbol RefSeq number Description
Extracellular matrix proteins
Collagens and ECM structural constituents
COL1A1

NM_000088

Homo sapiens collagen, type I, alpha 1

183526

2.06

COL1A2

NM_000089

Homo sapiens collagen, type I, alpha 2

142138

1.59

COL3A1

NM_000090

Homo sapiens collagen, type III, alpha 1

3108

0.03

COL4A1

NM_001845

Homo sapiens collagen, type IV, alpha 1

5622

0.06

COL4A2

NM_001846

Homo sapiens collagen, type IV, alpha 2

44164

0.49

COL5A1

NM_000093

Homo sapiens collagen, type V, alpha 1

32129

0.36

COL5A2

NM_000393

Homo sapiens collagen, type V, alpha 2

19919

0.22

COL6A1

NM_001848

Homo sapiens collagen, type VI, alpha 1

117011

1.31

COL6A2

NM_058174

Homo sapiens collagen, type VI, alpha 2

11593

0.13

COL6A3

NM_004369

Homo sapiens collagen, type VI, alpha 3

1112

0.01

COL7A1

NM_000094

Homo sapiens collagen, type VII, alpha 1

1136

0.01

COL12A1

NM_004370

Homo sapiens collagen, type XII, alpha 1

17353

0.19

COL16A1

NM_001856

Homo sapiens collagen, type XVI, alpha 1

17366

0.19

DCN

NM_001920

Homo sapiens decorin

22826

0.25

FN1

NM_054034

Homo sapiens fibronectin 1

6213

0.07

LUM

NM_002345

Homo sapiens lumican

7747

0.09

Basement membrane constituents
LAMA2

NM_000426

Homo sapiens laminin, alpha 2

804

0.01

LAMB1

NM_002291

Homo sapiens laminin, beta 1

10371

0.11

LAMB2

NM_002292

Homo sapiens laminin, beta 2 (laminin S)

16172

0.18

LAMC1

NM_002293

Homo sapiens laminin, gamma 1 (formerly LAMB2)

10072

0.11

Cell adhesion molecules
Cell-matrix adhesion
ITGA5

NM_002205

Homo sapiens integrin, alpha 5 (fibronectin receptor, alpha
polypeptide)

3324

0.04

ITGA6

NM_000210

Homo sapiens integrin, alpha 6

1168

0.01

ITGA7

NM_002206

Homo sapiens integrin, alpha 7

7553

0.08

ITGB1

NM_133376

Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)

6616

0.07

ITGB5

NM_002213

Homo sapiens integrin, beta 5

4324

0.05

MMP1

NM_002421

Homo sapiens matrix metallopeptidase 1 (interstitial collagenase)

4368

0.05

TIMP1

NM_003254

Homo sapiens TIMP metallopeptidase inhibitor 1

42809

0.48

TIMP2

NM_003255

Homo sapiens TIMP metallopeptidase inhibitor 2

83481

0.93

TIMP3

NM_000362

Homo sapiens TIMP metallopeptidase inhibitor 3

36463

0.41

ECM proteases and protease inhibitors

Non-muscle and muscle markers
DES

NM_001927

Homo sapiens desmin

8119

0.09

MYO1C

NM_033375

Homo sapiens myosin IC

33956

0.38

MYLK

NM_053025

Homo sapiens myosin light chain kinase

12346

0.14
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Table 1 Differential expression analysis in primary human neonatal ADSC (Continued)
MYLK

NM_053025

Homo sapiens myosin light chain kinase

18846

0.21

MYH9

NM_002473

Homo sapiens myosin, heavy chain 9, non-muscle

15884

0.18

MYL6

NM_079423

Homo sapiens myosin, light chain 6, alkali, smooth muscle and
non-muscle

51777

0.58

a
The fold difference represents the ratio of intensity of each gene hybridized with the RNA isolated from hADSC normalized to the intensity of GAPDH gene. Each
array was processed in an identical manner and the number represents an average of triplicate experiments from three independent cell isolates. Each gene is
demarcated by the Genbank accession number, the description of the gene and the common name. Genes are grouped by their distinct functional categories.
ADSC, adipose-derived stem cells; ECM, extracellular matrix.

Figure 2 Intramuscular transplantation of human neonatal ADSC into Col6a1−/−Rag1−/− mice. (A) Representative in vivo images showing
the hindlimbs that received a single intramuscular injection of ADSC. Cells were cultured in the presence of a red fluorescent lipophilic dye
(DiOC18), and 0.5 × 106 DiOC18-ADSC were injected into the left GCM. The right GCM served as the control. IVIS imaging was performed at one,
two, three, four and six weeks post-transplantation. (B) Morphometric analysis of DiOC18-ADSC engraftment into the GCM was performed at one,
two, three, four and six weeks post-transplantation. The percentage of engrafted cells was determined by staining of transplanted GCM with
lamin A/C antibody as a marker for donor cells and by counting lamin A/C positive-cells on at least fifty 7 μm sections. As an additional approach,
the total number of DiOC18-positive ADSC was calculated using FACS analysis of a single-cell suspension of the GCM containing ADSC transplant.
The vertical axis shows the percentage (%) of engrafted ADSC per injected muscle. The horizontal axis shows the time point after transplantation
in weeks (w). (C) Morphometric analysis of α1(VI)-positive myofibers in the GCM transplanted with ADSC. The number of α1(VI)-positive myofibers
was determined by counting a minimum of fifty 7 μm sections per animal. The vertical axis shows the number of α1(VI)-positive myofibers per
section. The horizontal axis shows the time point after transplantation in weeks (w). In all studies, at least five animals were analyzed per time
point. Error bars represent means ± SEM. ADSC, adipose-derived stem cells; FACS, fluorescence-activated cell sorting; GCM, gastrocnemius muscle;
SEM, standard error of the mean.
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Figure 3 Histochemical and indirect immunofluorescence analyses of GCM biopsies after transplantation of human neonatal ADSC into
Col6a1−/−Rag1−/− mice. Muscle biopsies were collected at one, two, three, four, and six weeks after transplantation under homeostatic
conditions. Time points are indicated to the left of the panels. (A) Hematoxylin and eosin staining (H & E) of the ADSC-treated GCM. (B, C) Indirect
immunofluorescence detection of ADSC-derived collagen VI in the transplanted GCM. Donor cells were detected with anti-human lamin A/C
antibodies (AlexaFluor488, green) and collagen VI-positive myofibers were detected with anti-α1(VI)-collagen antibodies (AlexaFluor594, red).
Images were taken from representative sections at low (B) and high (C) magnification, respectively. (D, E) Co-localization of the ADSC-donated
α1(VI)-collagen (AlexaFluor488, green) and basement-membrane-associated type IV collagen (AlexaFluor594, red) in ADSC-treated muscles.
Images were taken from representative sections at low (D) and high (E) magnification, respectively. Nuclei were stained with DAPI (blue). Scale
bar, 100 μm (low magnification) and 25 μm (high magnification), respectively. ADSC, adipose-derived stem cells; DAPI, 4′,6-diamidino-2-phenyl
indol; GCM, gastrocnemius muscle.

transplantation the ADSC were preferentially found in the
connective tissue of perimysium and the periphery of
muscle fascicles with occasional cells in endomysial space.
Furthermore, the presence of an excessive number of
transplanted cells during initial engraftment stages resulted in substantial enlargement of perimysial space and
significant production of collagen VI into adjacent tissue.
Remarkably, in the next two to six weeks, prominent and
continuous collagen VI staining was strongly associated
with endomysial connective tissue and many surrounding
individual myofibers, although, some transplanted cells
continued to reside in the perimysium space (Figure 3B
and C). The majority of the ADSC was able to migrate
from primary perimysial residence to distal sites along
endomysium, possibly in response to microenvironmental
cues, and continued to donate therapeutic collagen VI protein to surrounding myofibers. In addition, the ADSC were
positioned in close proximity to neighboring interstitial

fibroblasts. Morphometric analysis showed a marked increase (two-fold) in α1(VI) collagen-positive myofibers
at the sixth week as compared to the first week of transplantation (Figure 2C). It is well known that secreted
collagen VI molecules form an extended microfilament
network particularly abundant close to the cells, which
has been suggested to play a role in anchoring the basement membrane of non-epithelial cells to the underlying connective tissue. Using double immunostaining
with antibodies specific for type IV collagen, which is an
integral component of the basement membrane, and α1
(VI) collagen, we showed overlapping fluorescent signals of both proteins at the basement membrane of individual myofibers, suggesting functionality of the
ADSC-secreted collagen VI protein (Figure 3D and E).
Col6a1−/− mice homozygous for the Rag1 mutation are
immunodeficient as they completely lack mature B and
T lymphocytes but they display other fully functional
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inflammatory cells. To test whether transplantation
with the ADSC resulted in any immune recognition, inflammatory cell infiltration was assessed by staining
muscle tissue with CD11b, as a marker for macrophages, and lamin A/C, as a marker for donor cells. As
seen in Figure 4A, a similar degree of infiltration by
CD11b-positive cells was found in both untreated and
ADSC-treated muscle. Overall, our data indicate that
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ADSC have engrafted, migrated and produced therapeutic
collagen VI protein in muscle of Col6a1−/−Rag1−/− mice.
Intramuscular transplantation of ADSC into
Col6a1−/−Rag1−/− mice under injury/regeneration conditions

Since the muscle phenotype of the Col6a1−/− mice is
much milder than that of human patients, we used cardiotoxin (CTX) to injure the GCM muscle of the neonatal

Figure 4 Analysis of muscle tissue infiltration with CD11b-positive cells after ADSC transplantation. (A) Indirect immunofluorescence
assessment of the infiltrating CD11b-positive leukocytes (green) in untreated and ADSC-treated muscles of Col6a1−/−Rag1−/− mice at different
time points after transplantation. (B) Indirect immunofluorescence assessment of the infiltrating CD11b-positive leukocytes (green) in CTX-injured
muscles with or without ADSC transplantation. In all cases, ADSC were detected with anti-human lamin A/C antibodies (red), whereas infiltrating
CD11b-positive cells were detected with anti-CD11b antibodies (green). Time points are indicated to the left of the panels. Corresponding treatment is
shown on top of the panels. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. ADSC, adipose-derived stem cells; CTX, cardiotoxin; DAPI,
4′,6-diamidino-2-phenyl indol.
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Col6a1−/−Rag1−/− mice and thereby exacerbate the muscle
abnormality. In order to enhance the regenerative response from donor stem cells, DiOC18-ADSC were
injected into the left GCM two days prior to CTX injury
and were traced at various time points after transplantation by systematic screening of histological sections. The
right GCM was injected with CTX only as internal
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control. As expected, the direct injection of CTX into the
GCM resulted in severe tissue injury in both control and
ADSC transplanted muscle tissues. Histological analysis
demonstrated global myofiber fragmentation and edema
at one week after cell transplantation and five days after
CTX treatment (Figure 5A). The CTX-injured muscle
showed necrosis, disorganized muscle architecture and

Figure 5 Histochemical and indirect immunofluorescent analyses of GCM biopsies after ADSC transplantation and CTX injury. Biopsies
were collected at one, two, three, four and six weeks after ADSC transplantation (indicated to the left of the panels). (A) Hematoxylin and eosin
staining (H & E) staining of ADSC-treated and CTX-injured GCM. (B, C) Indirect immunofluorescent detection of ADSC-derived collagen VI was
performed using anti-lamin A/C (green) and anti-α1(VI) collagen (red) antibodies. Images were taken from representative sections at low (B) and
high (C) magnification, respectively. Progressive, time-dependent spreading of transplanted ADSC within muscle tissue and donation of type VI
collagen into perimysium and endomysium is apparent. (D, E) Indirect immunofluorescence detection of the α1(VI) collagen (green) and type IV
collagen (red) co-localization at the basement membrane of the ADSC-treated, CTX-injured GCM. Images were taken from representative sections
at low (D) and high (E) magnification, respectively. Nuclei were stained with DAPI (blue). Scale bar, 100 μm (low magnification) and 25 μm (high
magnification), respectively. (F, G) Indirect immunofluorescence detection of lamin A/C (green) and type IV collagen (blue) in muscle biopsy after
30 days. Arrow points to donor cells (dc). P, perimysium; e, endomysium. (H) Indirect immunofluorescence detection of Pax7 (green), lamin A/C
(red) and type IV collagen (blue) in muscle biopsy after 30 days. (I) Indirect immunofluorescence detection of Pax7 (green), α1(VI) collagen (red)
and type IV collagen (blue) in muscle biopsy after 30 days. Arrows point to Pax7-positive (green) satellite cells. Scale bar, 100 μm. ADSC,
adipose-derived stem cells; CTX, cardiotoxin; DAPI, 4′,6-diamidino-2-phenyl indol; GCM, gastrocnemius muscle.
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infiltration with mononucleated cells across the sectional
area, mostly attributed to inflammatory cells (Figures 4B
and 5A). Although the majority of transplanted cells were
detected in perimysial space, small groups of the transplanted ADSC were readily found in close proximity to
the injury site with already detectable collagen VI-positive
myofibers. At two weeks post-ADSC injection, the CTXtreated muscles had numerous clusters of regenerating
myofibers as judged by their small diameter, basophilic
cytoplasm and centrally located nuclei. The level of engraftment did not change significantly and sustained at
the level of 20% up to six weeks after transplantation
(Figure 6A). Importantly, in CTX-treated muscles receiving ADSC transplant the number of collagen VI positive
myofibers significantly increased (four-fold) in next three
to six weeks (Figure 6B). Furthermore, the muscle morphology at three to six weeks post-ADSC injection/CTX injury was not different from that of the non-injured control
muscles except for the presence of numerous myofibers
with centrally positioned nuclei (Figures 5B-E), a known
hallmark of recent muscle regeneration. Moreover, the
number of CD11b infiltrating macrophages reduced dramatically, indicating the completion of the acute tissue
damage phase (Figure 4B). The functionality of the ADSCproduced collagen VI was confirmed by double immunostaining with collagen α1 (VI) and IV antibodies, showing
co-localization of both proteins at the basement membrane of individual myofibers (Figure 5D and E). It is well
known that the muscle-specific stem cells, such as satellite
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cells, have a unique anatomical location and are positioned
between the sarcolemma and the basal lamina of the
muscle fibers. To see whether the transplanted ADSC can
contribute to the satellite cell compartment and/or participate in formation of new myofibers, we examined the location of ADSC on the sections positively stained for
donor engrafts in relation to the position of Pax7-positive
satellite cells. In all examined sections of three and four
week biopsies, human lamin A/C-positive cells were detected residing in the interstitial space of perimysium as
well as endomysium surrounding individual muscle fibers
(Figure 5F, G). Double-immunostaining with antibodies
for human lamin Α/C and mouse Pax7 did not show any
overlapping signals (Figure 5H), suggesting that donor
cells had not entered the satellite cell niche or acquired
muscle stem cell phenotype (Figure 5H). Moreover, regenerating and newly-formed collagen VI-positive myofibers
did not show any lamin A/C-positive nuclei (Figure 5C),
suggesting that the donor ADSC had not fused with
mouse muscle fibers and had not directly participated
in the formation of newly regenerating fibers. However,
it was evident that ADSC-produced collagen VI was
present at the basement membrane surrounding Pax7
cells (Figure 5I), suggesting that restored collagen VI
expression may provide better mechanical properties to
satellite cell niche and affect satellite cell activity. Overall, our data strongly suggest that collagen VI-donating
ADSC were able to migrate intramuscularly in response
to pro-migratory factors released in the course of CTX-

Figure 6 Comparative morphometric analysis of ADSC engraftment and type VI collagen distribution in homeostatic and CTX-treated
GCM, respectively. Analysis was performed at one, two, three, four and six weeks post-transplantation and CTX injury. (A) Engraftment of ADSC
into the GCM with or without CTX treatment. The vertical axis shows the percentage (%) of engrafted ADSC per injected muscle. The horizontal
axis shows the time point after transplantation in weeks (w). (B) Morphometric analysis of α1(VI)-positive myofibers in the transplanted GCM with
or without CTX treatment. The vertical axis shows the number of α1(VI)-positive myofibers per section. The horizontal axis shows the time point
after transplantation in weeks (w). In all cases, ADSC were detected with anti-lamin A/C antibodies. The percentage of engrafted cells and the
number of α1(VI)-positive myofibers were determined on at least fifty 7 μm cryosections, respectively, covering approximately 125 mm3 of muscle
tissue. In all studies, at least five animals were analyzed per time point. Data is presented as average ± SD. ADSC, adipose-derived stem cells; CTX,
cardiotoxin; GCM, gastrocnemius muscle; SD, standard deviation.
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induced injury and regeneration, and they continued
to produce collagen VI protein in muscle of Col6a1−/−
Rag1−/− mice.

Discussion
This study exploits the novel application of stem cell
therapy specific for COL6 CMD. We tested the hypothesis that collagen VI secreted by ADSC in the ECM can
ameliorate the genetic impairment of skeletal muscles in
the COL6 CMD mouse model. We developed a novel
procedure for isolation of ADSC from neonatal human
skin discarded after newborn circumcision and demonstrated that established cultures represent a morphologically homogeneous population of cells with phenotypic and
functional features of mesenchymal progenitors. Also, we
conducted a comprehensive gene expression profile of
ADSC with special emphasis on ECM and adhesion
molecules. Furthermore, we showed for the first time
that locally transplanted ADSC are capable of donating
collagen VI protein into muscle of Col6a1−/− mice under
physiological and CTX-injury/regeneration conditions.
Adult stem cells represent a diverse group of stem cells,
which are characterized by their ability to self-renew and
their ability to differentiate along multiple lineage pathways. These unique features make these cells an attractive
therapeutic option for transplantation and regeneration
of damaged tissues. The most common type of adult
stem cells is multipotent MSC, which can be isolated
from several sources, including bone marrow, adipose
tissue, dental pulp, placenta, umbilical cord and fallopian
tube [23]. MSC isolated originally from bone marrow are
defined as fibroblast-like cells with extensive proliferation
capacity in culture and the ability to differentiate in vitro
into various connective tissue cell types [28,29]. Recent
advances in stem cell biology have shown that adult
stem cells isolated from adipose tissue exhibit a number
of properties suggesting the feasibility of their use as
therapeutic cells [22]. The most important features of
adipose tissue are its abundance in the body, relatively
simple isolation procedures, expandability to relatively
large quantities under minimal conditions and the ability
to engraft after local or systemic reintroduction [22,23].
Here, we developed a novel procedure for the isolation of ADSC from neonatal human skin discarded after
newborn circumcision and demonstrated that established
cultures represent population of cells with features of mesenchymal progenitors. The developed isolation protocol
proved to be a reliable approach to prepare a homogeneous fraction of human ADSC. Our antigenic cell surface
profile is consistent with a previously published immunophenotypic analysis available for adult stem cells [23]. A
hallmark characteristic of stem cells is their self-renewal
potential and ability to differentiate into several cell lineages in vitro with the appropriate inductive media. The
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established ADSC cultures were able to differentiate toward adipogenic, osteogenic and chondrogenic lineages
in vitro in the presence of lineage specific differentiation
factors. Successful differentiation was confirmed by morphological changes demonstrated using lineage specific
staining and gene expression analysis of genetic markers
for the cell type of interest. Overall, these results are consistent with previously published works.
Multiple gene expression profiling studies have shown
that adult stem cells, in particular MSC, can produce a
vast array of proteins, including growth factors, cytokines,
ECM and adhesion molecules [30]. However, no data are
available regarding the expression of ECM and related
genes by human neonatal ADSC. Our comprehensive
gene expression analysis has shown that neonatal ADSC
express a plethora of various ECM molecules, including
many collagens and laminins, as well as adhesion molecules and other ECM-related genes. Of special interest to
this study is collagen VI, ultimate cause of COL6 CMD.
We show that ADSC produce a significant level of all
three collagen VI mRNAs, in particular COL6A1. The use
of ADSC for the treatment of COL6 CMD thus seems to
be a logical choice since the cells are able to supply continuously the missing normal collagen VI protein.
Cell-based therapy has been explored for different
types of muscular dystrophies, in particular, Duchenne
muscular dystrophy [19,31]. The majority of these studies
evaluated muscle derived progenitor or stem cells, such as
myoblasts, side population cells, myogenic endothelial
cells and mesoangioblasts. Several studies have tested
stem cells derived from non-muscle tissues [32-34]. The
transplanted cells were found to have limited ability to
regenerate muscle fibers but were capable of reducing
inflammation through trophic effects produced by transplanted cells [33,35]. Thus, even though a range of therapeutic approaches have been investigated for traditional
muscular dystrophies, there is a need to develop treatment
strategies that specifically target muscle ECM alterations.
In the skeletal muscle, collagen VI is synthesized by
muscle fibroblasts rather than muscle cells [8]. This is in
stark contrast to most other muscular dystrophies in
which the gene mutations usually involve intracellular or
cell surface proteins produced by muscle cells. Therefore,
the ability of stem cells to differentiate into muscle cells is
not crucial for the therapeutic intervention of COL6
CMD. Moreover, the multi-lineage differentiation capacity
of these cells is ideally suited for therapeutic intervention
of COL6 CMD in which different connective tissue cell
types need to be replenished. Also, apart from the cell regeneration capacity, an emerging therapeutic application
of the stem cell therapy takes advantage of their
ability to secrete cytokines and growth factors that
are anti-apoptotic, pro-angiogenic, anti-inflammatory and
anti-fibrotic [36]. Increased muscle cell apoptosis and
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interstitial fibrosis are typical pathological features of
CMDs; therefore, stem cell transplantation likely will
be beneficial even without cell differentiation and
regeneration.
In this study, the therapeutic potential of neonatal
ADSC was examined after local intramuscular injection
into the GCM of Col6a1−/−Rag1−/− mice, allowing human
cell transplantation without immune rejection. Our study
has shown for the first time that ADSC contributed robustly to the collagen VI-deficient GCM by providing
efficient engraftment, wide-distribution of therapeutic
cells in muscle tissue, continuous production of collagen
VI protein by engrafted cells throughout the observation
period and proper assembly of collagen VI microfibrils in
the interstitial connective tissue of muscle, thus achieving
restoration of the affected muscle basement membrane.
One of the striking observations is the location of donor
cells within the muscle tissue at initial stages of transplantation. During the first two weeks, the vast majority of
ADSC was preferentially detected in perimysial space with
very few cells in endomysium. Such unique locale could
be explained by the fact that the muscle ECM, which is
rich in connective tissue and adhesion proteins, may provide a proper environment for firm anchorage/attachment
of ADSC. Once cells are acclimated to the perimysial
environment, they start to migrate along endomysium,
possibly in response to pro-migratory factors secreted
by resident interstitial fibroblasts and muscle cells. Importantly, the number of α1(VI) collagen-positive myofibers
was markedly increased (two-fold) at week six as compared to the first week of transplantation, suggesting the
possibility of long-term commitment of ADSC in the
muscle environment.
The capacity of neonatal ADSC to participate in the
regeneration of skeletal muscle was further evaluated
using the CTX-induced myonecrosis model with actively
ongoing regeneration and remodeling of muscle tissue.
Several important observations were made during these
studies. It is believed that the depletion of the satellite
cell pool with consequent irreversible muscle degeneration
is responsible for terminal muscle failure in DMD, COL6
CMD and, possibly, other muscular dystrophies [37,38].
Restoration of the regeneration potential of muscle tissue
by transplanted stem cells may provide long-term efficacy
for muscle homeostasis. This notion is strongly supported
by a recent observation that transplantation of wild-type
fibroblasts into Col6a1 null mice was able to ameliorate
regeneration and satellite cell homeostasis by restoring
muscle mechanical properties and satellite cell activity
[38]. However, these effects may be somehow limited by
the fact that the grafted cells are differentiated fibroblasts.
Our data clearly demonstrate that ADSC are able to
colonize in muscle, sustaining their long-term maintenance and the continuous replenishment of collagen VI.
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However, our data demonstrated that ADSC do not directly participate in the repair of CTX-damaged muscle
fibers. Immunofluorescent analysis did not show any
ADSC entering the satellite niche, as judged by the position of lamin A/C-positive cells in newly regenerated
myofibers. In addition, double-immunostaining of CTXtreated biopsies with lamin A/C (donor human cells) and
Pax7 (a marker for both quiescent and activated satellite
cells) antibodies did not show any overlapping signals.
Taken together, these data suggest that ADSC may not
possess cell-autonomous properties supporting myogenic
differentiation in vivo. Also, it may suggest that CTX treatment alone does not induce or enhance production of
supporting factors to provide a more conducive environment for ADSC to go through myogenic commitment.
Nevertheless, CTX-treated muscles receiving the ADSC
transplant showed a significant increase (four-fold) in the
number of collagen VI-positive myofibers at the sixth
week compared to the first week of transplantation and
a two-fold increase compared to transplanted muscle
without CTX-injury at the sixth week. It is important to
note that ADSC engraftment was not dependent on ablative injury, as cells also contributed at high efficiency
(approximately 20%) after transplantation into the GCM
and sustained at this level throughout the study. However,
it is interesting to note that after CTX-injury collagen VIdonating ADSC were able to migrate intramuscularly from
their initial perimysial locale shortly after transplantation
to the CTX-injected site, and eventually repopulated a
significant area of the damaged tissue and adjacent
myofibers. This directional migration from perimysium
to endomysium could possibly be induced in response
to pro-migratory factors released in the course of CTXinjury and regeneration, elicited by various mechanisms.
As one explanation, it is likely that pro-inflammatory
cytokines, chemokines and growth factors that typically
result in homing of immune cells to a damaged site are
released from muscle resident cells, stimulating directional migration of ADSC within muscle tissue. In fact,
a prominent feature of CTX-injured muscle is a striking
inflammatory infiltrate of immune cells, such as macrophages and neutrophils. Also, it is well known that CCR2
and CXCR2 are major regulators of induced macrophage
and neutrophils trafficking in vivo [39,40]. In addition, the
CXCR4-CXCL12 chemotactic axis was shown to play a
significant role in regulating migration of both proliferating and terminally differentiated muscle cells [41]. Based
on our assessment of chemokine receptors on ADSC, it is
plausible that ADSC expressing those receptors can be recruited to the CTX-damaged site by the chemotactic
mechanisms of inflammatory and satellite cells, respectively. Also, it is possible that abnormal signaling due to
the deficient ECM leads to secretion of various chemokines, which may activate corresponding receptors on
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ADSC and facilitate migration toward the highest concentration of chemokine(s). Together, these observations suggest that mobilization of ADSC in CTX-damaged muscle
may highly depend on the local inflammatory state rather
than other factors. The ability of ADSC to donate the protein of interest to the injured muscle strongly supports the
possibility of stem cell therapy for COL6 CMD, which exhibits substantially more severe myopathology than the
mouse model.

Conclusions
In summary, our data provided proof-of-concept that
ADSC can serve as a ‘cell factory’ to produce ECM molecules, such as collagen VI, which can potentially correct
the protein deficiency of COL6 CMD patients. Our data
also suggest that a systemic administration of stem cells
can be beneficial to counteract the disease phenotype in
the different muscles. A significant obstacle in designing
stem cell-based therapy for COL6 CMD and other muscular dystrophies is the necessity to reach the entire body
musculature, a problem that cannot be easily overcome
unless systemic transplantation protocols are proved to be
effective. Further investigations are required to address
these important issues. Our results provide evidence supporting the suitability of ADSC as a prospective therapy
for COL6 CMD. If successful, the therapeutic capabilities
of stem cells could be extended to other ECM-related
muscular dystrophies that are in need of more effective
treatment options.
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